Current:Home > StocksHow well does a new Alzheimer's drug work for those most at risk?-DB Wealth Institute B2 Expert Reviews
How well does a new Alzheimer's drug work for those most at risk?
View Date:2024-12-23 23:15:48
Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts.
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people.
While some saw it as undeniable progress for a disease with no other proven treatment, others urged caution because of severe side effects and the finding of only a "modest" effect. Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School, has another concern: the racial and ethnic makeup of the trial.
The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it still was not enough to definitively say if the drug is effective for Black people.
"[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," Jackson, director of the Community Access, Recruitment, and Engagement Research Center, says.
The makers of lecanemab say the trial was able to enroll more Black and Hispanic patients by removing some of the requirements that had been in place for previous trials. They cite tapping into community outreach groups and making it "easy for the patients to enroll into the study, and we made it easy for the patients to actually continue to participate in the study," says Shobha Dhadda, Vice President of Biostatistics and clinical development operations for Neurology at the pharmaceutical company Esai.
The trial enrollment comes close to reaching the racial breakdown of people 65 and older according to the census, but Jackson says that's the wrong goal. Black and Hispanic people, women, and those with a genetic predisposition are all at disproportionately high risk for developing Alzheimer's. Jackson says companies should be overrepresenting these groups in their trials.
"If we continue to study privileged populations ... we're leaving huge questions unanswered about how Alzheimer's works, how it progresses, and what are the significant risk factors," he says. "So when you're designing a study, you should really worry less about the census and more about trying to represent those who are disproportionately affected."
On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.
Have suggestions for what we should cover in future episodes? Email us at [email protected].
This episode was produced by Liz Metzger and edited by Gabriel Spitzer. Anil Oza contributed additional reporting and checked the facts. Patrick Murray was the audio engineer.
veryGood! (7)
Related
- Traveling to Las Vegas? Here Are the Best Black Friday Hotel Deals
- 'Dangerous and unsanitary' conditions at Georgia jail violate Constitution, feds say
- Louisville officials mourn victims of 'unthinkable' plant explosion amid investigation
- Nelly will not face charges after St. Louis casino arrest for drug possession
- Taylor Swift drops Christmas merchandise collection, including for 'Tortured Poets' era
- Dramatic video shows Phoenix police rescue, pull man from car submerged in pool: Watch
- Today’s Savannah Guthrie, Al Roker and More React to Craig Melvin Replacing Hoda Kotb as Co-Anchor
- She's a trans actress and 'a warrior.' Now, this 'Emilia Pérez' star could make history.
- Smithfield agrees to pay $2 million to resolve child labor allegations at Minnesota meat plant
- Gold is suddenly not so glittery after Trump’s White House victory
Ranking
- 'Treacherous conditions' in NYC: Firefighters battling record number of brush fires
- Atlanta man dies in shootout after police chase that also kills police dog
- Joan says 'Yes!' to 'Golden Bachelorette' finale fantasy beach proposal. Who did she pick?
- Mason Bates’ Met-bound opera ‘Kavalier & Clay’ based on Michael Chabon novel premieres in Indiana
- Cruel Intentions' Brooke Lena Johnson Teases the Biggest Differences Between the Show and the 1999 Film
- She's a trans actress and 'a warrior.' Now, this 'Emilia Pérez' star could make history.
- 'Serial swatter': 18-year-old pleads guilty to making nearly 400 bomb threats, mass shooting calls
- Mike Tyson employs two trainers who 'work like a dream team' as Jake Paul fight nears
Recommendation
-
Black and Latino families displaced from Palm Springs neighborhood reach $27M tentative settlement
-
Georgia lawmaker proposes new gun safety policies after school shooting
-
New Orleans marks with parade the 64th anniversary of 4 little girls integrating city schools
-
More human remains from Philadelphia’s 1985 MOVE bombing have been found at a museum
-
The NBA Cup is here. We ranked the best group stage games each night
-
'Survivor' 47, Episode 9: Jeff Probst gave players another shocking twist. Who went home?
-
Powell says Fed will likely cut rates cautiously given persistent inflation pressures
-
Joan says 'Yes!' to 'Golden Bachelorette' finale fantasy beach proposal. Who did she pick?